Summit Therapeutics (SMMT) Accounts Payables (2018 - 2026)
Summit Therapeutics' (SMMT) quarterly Accounts Payables came in at $22.9 million in Q2 2026, little changed YoY from $23.0 million in Q2 2025, and down 16.89% on a QoQ basis from $27.5 million in Q1 2026.
Summit Therapeutics (SMMT) Accounts Payables (2018 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 9 years of Accounts Payables data on file, last reported at $22.9 million in Q2 2026.
- Quarterly Accounts Payables changed 0.37% year-over-year to $22.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $22.9 million (changed 0.37% YoY) and the FY2025 annual result came in at $20.3 million, up 337.7% from the prior year.
- Accounts Payables retreated to $22.9 million in Q2 2026, from $27.5 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $27.5 million in Q1 2026 to a low of $355000.0 in Q4 2022.
- A 5-year average of $8.8 million and a median of $4.1 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables plunged 91.88% — and 2024, when it soared 797.32%.
- Tracing SMMT's Accounts Payables over 5 years: stood at $355000.0 in 2022, then jumped by 651.27% to $2.7 million in 2023, then surged by 73.83% to $4.6 million in 2024, then jumped by 337.7% to $20.3 million in 2025, then increased by 12.83% to $22.9 million in 2026.
- The last three Accounts Payables figures came in at $22.9 million (Q2 2026), $27.5 million (Q1 2026), and $20.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 22.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.90 Mn |
| Mar 31, 2026 | 27.55 Mn |
| Dec 31, 2025 | 20.29 Mn |
| Sep 30, 2025 | 22.25 Mn |
| Jun 30, 2025 | 22.98 Mn |
| Mar 31, 2025 | 4.99 Mn |
| Dec 31, 2024 | 4.64 Mn |
| Sep 30, 2024 | 3.25 Mn |
| Jun 30, 2024 | 3.34 Mn |
| Mar 31, 2024 | 6.37 Mn |
| Dec 31, 2023 | 2.67 Mn |
| Sep 30, 2023 | 3.31 Mn |
| Jun 30, 2023 | 987,000.00 |
| Mar 31, 2023 | 710,000.00 |
| Dec 31, 2022 | 355,000.00 |
| Sep 30, 2022 | 1.43 Mn |
| Jun 30, 2022 | 3.57 Mn |
| Mar 31, 2022 | 6.96 Mn |
| Dec 31, 2021 | 4.37 Mn |
| Sep 30, 2021 | 5.88 Mn |